Trial Profile
A Phase II Study of Capecitabine and Lapatinib in Squamous Cell Carcinoma of the Head and Neck
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Lapatinib (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 28 Aug 2018 Status changed from active, no longer recruiting to completed.
- 24 Jan 2017 Planned primary completion date changed from 1 Oct 2013 to 1 Mar 2017.
- 19 May 2016 Primary endpoint has been met. (Overall survival), as per an article published in the Cancer.